These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33879599)

  • 1. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
    Yeh WZ; Widyastuti PA; Van der Walt A; Stankovich J; Havrdova E; Horakova D; Vodehnalova K; Ozakbas S; Eichau S; Duquette P; Kalincik T; Patti F; Boz C; Terzi M; Yamout BI; Lechner-Scott J; Sola P; Skibina OG; Barnett M; Onofrj M; Sá MJ; McCombe PA; Grammond P; Ampapa R; Grand'Maison F; Bergamaschi R; Spitaleri DLA; Van Pesch V; Cartechini E; Hodgkinson S; Soysal A; Saiz A; Gresle M; Uher T; Maimone D; Turkoglu R; Hupperts RM; Amato MP; Granella F; Oreja-Guevara C; Altintas A; Macdonell RA; Castillo-Trivino T; Butzkueven H; Alroughani R; Jokubaitis VG;
    Neurology; 2021 Jun; 96(24):e2989-e3002. PubMed ID: 33879599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis.
    Haben S; Ciplea AI; Tokic M; Timmesfeld N; Thiel S; Gold R; Langer-Gould AM; Hellwig K
    J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):151-157. PubMed ID: 37536925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of disease-modifying treatments in multiple sclerosis to plan a pregnancy: A retrospective registry study.
    Villaverde-González R; Candeliere-Merlicco A; Alonso-Frías MA; Aparicio Castro E; Carrillo Alcaraz A; Mallada Frechín J; Pérez Sempere Á
    Mult Scler Relat Disord; 2020 Nov; 46():102518. PubMed ID: 32977075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
    Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
    J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
    Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H;
    Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A
    JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis.
    Hellwig K; Verdun di Cantogno E; Sabidó M
    Ther Adv Neurol Disord; 2021; 14():17562864211051012. PubMed ID: 34876925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
    Hughes SE; Spelman T; Gray OM; Boz C; Trojano M; Lugaresi A; Izquierdo G; Duquette P; Girard M; Grand'Maison F; Grammond P; Oreja-Guevara C; Hupperts R; Bergamaschi R; Giuliani G; Lechner-Scott J; Barnett M; Edite Rio M; van Pesch V; Amato MP; Iuliano G; Slee M; Verheul F; Cristiano E; Fernández-Bolaños R; Poehlau D; Saladino ML; Deri N; Cabrera-Gomez J; Vella N; Herbert J; Skromne E; Savino A; Shaw C; Moore F; Vucic S; Petkovska-Boskova T; McDonnell G; Hawkins S; Kee F; Butzkueven H;
    Mult Scler; 2014 May; 20(6):739-46. PubMed ID: 24107309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
    Signori A; Saccà F; Lanzillo R; Maniscalco GT; Signoriello E; Repice AM; Annovazzi P; Baroncini D; Clerico M; Binello E; Cerqua R; Mataluni G; Perini P; Bonavita S; Lavorgna L; Zarbo IR; Laroni A; Pareja-Gutierrez L; La Gioia S; Frigeni B; Barcella V; Frau J; Cocco E; Fenu G; Clerici VT; Sartori A; Rasia S; Cordioli C; Stromillo ML; Di Sapio A; Pontecorvo S; Grasso R; Barone S; Barrilà C; Russo CV; Esposito S; Ippolito D; Landi D; Visconti A; Sormani MP
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32801167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
    Lescot L; Lefort M; Leguy S; Le Page E; Vukusic S; Edan G; Kerbrat A; Lebrun-Frenay C; De Sèze J; Laplaud DA; Wiertlewski S; Leray E; Michel L
    Mult Scler Relat Disord; 2022 Dec; 68():104122. PubMed ID: 36037756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
    Roos I; Malpas C; Leray E; Casey R; Horakova D; Havrdova EK; Debouverie M; Patti F; De Seze J; Izquierdo G; Eichau S; Edan G; Prat A; Girard M; Ozakbas S; Grammond P; Zephir H; Ciron J; Maillart E; Moreau T; Amato MP; Labauge P; Alroughani R; Buzzard K; Skibina O; Terzi M; Laplaud DA; Berger E; Grand'Maison F; Lebrun-Frenay C; Cartechini E; Boz C; Lechner-Scott J; Clavelou P; Stankoff B; Prevost J; Kappos L; Pelletier J; Shaygannejad V; Yamout BI; Khoury SJ; Gerlach O; Spitaleri DLA; Van Pesch V; Gout O; Turkoglu R; Heinzlef O; Thouvenot E; McCombe PA; Soysal A; Bourre B; Slee M; Castillo-Trivino T; Bakchine S; Ampapa R; Butler EG; Wahab A; Macdonell RA; Aguera-Morales E; Cabre P; Ben NH; Van der Walt A; Laureys G; Van Hijfte L; Ramo-Tello CM; Maubeuge N; Hodgkinson S; Sánchez-Menoyo JL; Barnett MH; Labeyrie C; Vucic S; Sidhom Y; Gouider R; Csepany T; Sotoca J; de Gans K; Al-Asmi A; Fragoso YD; Vukusic S; Butzkueven H; Kalincik T;
    Neurology; 2022 Oct; 99(17):e1926-e1944. PubMed ID: 35977837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience.
    Zanghì A; D'Amico E; Callari G; Chisari CG; Borriello G; Grimaldi LME; Patti F
    Front Neurol; 2020; 11():105. PubMed ID: 32158424
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab for people with multiple sclerosis.
    Filippini G; Kruja J; Del Giovane C
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013874. PubMed ID: 34748215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fingolimod after natalizumab and the risk of short-term relapse.
    Jokubaitis VG; Li V; Kalincik T; Izquierdo G; Hodgkinson S; Alroughani R; Lechner-Scott J; Lugaresi A; Duquette P; Girard M; Barnett M; Grand'Maison F; Trojano M; Slee M; Giuliani G; Shaw C; Boz C; Spitaleri DL; Verheul F; Haartsen J; Liew D; Butzkueven H;
    Neurology; 2014 Apr; 82(14):1204-11. PubMed ID: 24610329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
    Spelman T; Horakova D; Ozakbas S; Alroughani R; Onofrj M; Kalincik T; Prat A; Terzi M; Grammond P; Patti F; Csepany T; Boz C; Lechner-Scott J; Granella F; Grand'Maison F; van der Walt A; Zhu C; Butzkueven H;
    Mult Scler Relat Disord; 2023 Feb; 70():104477. PubMed ID: 36746088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.